Skip to content

Study · Randomized controlled trial · 2014

7 results

A pilot study of the effects of the somatostatin analog pasireotide in postoperative dumping syndrome.

Deloose E, Bisschops R, Holvoet L, Arts J, De Wulf D, Caenepeel P, Lannoo M, Vanuytsel T, Andrews C, Tack J

Neurogastroenterology and motility20 Apr 2014Cited by 22 (Europe PMC)

PMID24750284 (opens in a new tab)DOI10.1111/nmo.12333 (opens in a new tab)PepBankPUB-24750284
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postoperative dumping syndrome, pulse rate increased by 8.2 ± 3.5 bpm with pasireotide versus 17.1 ± 2.8 bpm with placebo (p < 0.05).

    In plain wordsIn postoperative dumping syndrome, pasireotide reduced the pulse rate increase compared with placebo.

    Peptide
    Pasireotide
    Outcome
    DecreasePostprandial pulse rate increase
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    300 μg t.i.d. · subcutaneous · 2 weeksAs given in this study (human).

    Measurements

    Postprandial pulse rate increase
    8.2 bpm
    pasireotide 300 μg t.i.d.; ± 3.5
    Postprandial pulse rate increase
    17.1 bpm
    placebo; ± 2.8
    p value
    < 0.05
    pasireotide versus placebo

    Source sentences

    Summary
    Compared to placebo, pasireotide suppressed the increase in PR (17.1 ± 2.8 vs 8.2 ± 3.5 bpm; p < 0.05)
    2 context sentences
    Summary · context
    Randomized double-blind placebo-controlled cross-over study of nine patients (six women, 47 ± 4 years) with postoperative dumping.
    Summary · context
    Patients were treated for 2 weeks with placebo or pasireotide 300 μg s.c. t.i.d. with a 1-week wash-out in a randomized fashion. On day 13 and 14 of each treatment OGTT, DSSS, and solid and liquid gastric emptying (GE) were obtained.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postoperative dumping syndrome, nadir glycemia was 83.3 ± 9.5 mg/dL with pasireotide versus 55.6 ± 4.3 mg/dL with placebo (p = 0.007).

    In plain wordsIn postoperative dumping syndrome, pasireotide increased the lowest glucose level compared with placebo.

    Peptide
    Pasireotide
    Outcome
    IncreaseLate hypoglycemia nadir glycemia
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    300 μg t.i.d. · subcutaneous · 2 weeksAs given in this study (human).

    Measurements

    Nadir glycemia
    83.3 mg/dL
    pasireotide 300 μg t.i.d.; ± 9.5
    Nadir glycemia
    55.6 mg/dL
    placebo; ± 4.3
    p value
    0.007
    pasireotide versus placebo

    Source sentences

    Summary
    and late HG (nadir glycemia 55.6 ± 4.3 vs 83.3 ± 9.5 mg/dL; p = 0.007)
    2 context sentences
    Summary · context
    Randomized double-blind placebo-controlled cross-over study of nine patients (six women, 47 ± 4 years) with postoperative dumping.
    Summary · context
    Patients were treated for 2 weeks with placebo or pasireotide 300 μg s.c. t.i.d. with a 1-week wash-out in a randomized fashion. On day 13 and 14 of each treatment OGTT, DSSS, and solid and liquid gastric emptying (GE) were obtained.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postoperative dumping syndrome, pasireotide increased peak glycemia versus placebo (294.1 ± 33.3 vs 221.0 ± 23.1 mg/dL, p = 0.001).

    In plain wordsIn postoperative dumping syndrome, pasireotide increased peak blood glucose compared with placebo.

    Peptide
    Pasireotide
    Outcome
    IncreasePeak glycemia
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    300 μg t.i.d. · subcutaneous · 2 weeksAs given in this study (human).

    Measurements

    Peak glycemia
    294.1 mg/dL
    pasireotide 300 μg t.i.d.; ± 33.3
    Peak glycemia
    221 mg/dL
    placebo; ± 23.1
    p value
    0.001
    pasireotide versus placebo

    Source sentences

    Summary
    increased peak glycemia (294.1 ± 33.3 vs 221.0 ± 23.1 mg/dL; p = 0.001)
    2 context sentences
    Summary · context
    Randomized double-blind placebo-controlled cross-over study of nine patients (six women, 47 ± 4 years) with postoperative dumping.
    Summary · context
    Patients were treated for 2 weeks with placebo or pasireotide 300 μg s.c. t.i.d. with a 1-week wash-out in a randomized fashion. On day 13 and 14 of each treatment OGTT, DSSS, and solid and liquid gastric emptying (GE) were obtained.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postoperative dumping syndrome, pasireotide delayed solid gastric emptying versus placebo (83 ± 23 vs 43 ± 9 min, p = 0.05).

    In plain wordsIn postoperative dumping syndrome, pasireotide slowed stomach emptying of solids compared with placebo.

    Peptide
    Pasireotide
    Outcome
    IncreaseSolid gastric emptying half-time
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    300 μg t.i.d. · subcutaneous · 2 weeksAs given in this study (human).

    Measurements

    Solid gastric emptying half-time
    83 min
    pasireotide 300 μg t.i.d.; ± 23
    Solid gastric emptying half-time
    43 min
    placebo; ± 9
    p value
    0.05
    pasireotide versus placebo

    Source sentences

    Summary
    and delayed GE of solids (t1/2 83 ± 23 vs 43 ± 9 min; p = 0.05)
    2 context sentences
    Summary · context
    Randomized double-blind placebo-controlled cross-over study of nine patients (six women, 47 ± 4 years) with postoperative dumping.
    Summary · context
    Patients were treated for 2 weeks with placebo or pasireotide 300 μg s.c. t.i.d. with a 1-week wash-out in a randomized fashion. On day 13 and 14 of each treatment OGTT, DSSS, and solid and liquid gastric emptying (GE) were obtained.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In postoperative dumping syndrome, pasireotide delayed liquid gastric emptying versus placebo (70 ± 10 vs 40 ± 4 min, p = 0.05).

    In plain wordsIn postoperative dumping syndrome, pasireotide slowed stomach emptying of liquids compared with placebo.

    Peptide
    Pasireotide
    Outcome
    IncreaseLiquid gastric emptying half-time
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    300 μg t.i.d. · subcutaneous · 2 weeksAs given in this study (human).

    Measurements

    Liquid gastric emptying half-time
    70 min
    pasireotide 300 μg t.i.d.; ± 10
    Liquid gastric emptying half-time
    40 min
    placebo; ± 4
    p value
    0.05
    pasireotide versus placebo

    Source sentences

    Summary
    and liquids (t1/2 70 ± 10 vs 40 ± 4 min, p = 0.05).
    2 context sentences
    Summary · context
    Randomized double-blind placebo-controlled cross-over study of nine patients (six women, 47 ± 4 years) with postoperative dumping.
    Summary · context
    Patients were treated for 2 weeks with placebo or pasireotide 300 μg s.c. t.i.d. with a 1-week wash-out in a randomized fashion. On day 13 and 14 of each treatment OGTT, DSSS, and solid and liquid gastric emptying (GE) were obtained.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In postoperative dumping syndrome, dumping symptom scores did not differ significantly between pasireotide and placebo.

    In plain wordsIn postoperative dumping syndrome, symptom scores did not differ significantly between pasireotide and placebo.

    Peptide
    Pasireotide
    Outcome
    No significant changeDumping symptom severity score
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Disease Signs And Symptoms · Gastrointestinal
    Studied dose
    300 μg t.i.d. · subcutaneous · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    The differences in DSSS did not reach statistical significance.
    2 context sentences
    Summary · context
    Randomized double-blind placebo-controlled cross-over study of nine patients (six women, 47 ± 4 years) with postoperative dumping.
    Summary · context
    Patients were treated for 2 weeks with placebo or pasireotide 300 μg s.c. t.i.d. with a 1-week wash-out in a randomized fashion. On day 13 and 14 of each treatment OGTT, DSSS, and solid and liquid gastric emptying (GE) were obtained.
  7. 07HumanNon-randomized trialSafety outcome

    In postoperative dumping syndrome, two patients discontinued pasireotide because of adverse gastrointestinal events.

    In plain wordsIn postoperative dumping syndrome, two patients stopped pasireotide because of digestive adverse events.

    Peptide
    Pasireotide
    Outcome
    Not applicableDiscontinuation due to gastrointestinal events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    300 μg t.i.d. · subcutaneousAs given in this study (human).

    Measurements

    Patients who dropped out for gastrointestinal adverse events
    2 patients
    under pasireotide

    Source sentences

    Summary
    Two patients dropped out because of adverse gastrointestinal events under pasireotide.
    2 context sentences
    Summary · context
    Randomized double-blind placebo-controlled cross-over study of nine patients (six women, 47 ± 4 years) with postoperative dumping.
    Summary · context
    Patients were treated for 2 weeks with placebo or pasireotide 300 μg s.c. t.i.d. with a 1-week wash-out in a randomized fashion. On day 13 and 14 of each treatment OGTT, DSSS, and solid and liquid gastric emptying (GE) were obtained.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.